Evolving Regulation in Advanced Therapies 2025–2026: An Expert Brief

Advanced therapy medicinal products (ATMPs), including cell and gene therapies, are reshaping modern healthcare by enabling targeted and personalized treatment approaches. Regulatory frameworks are evolving in parallel to accommodate these therapies that are personalized, biologically complex, and often manufactured closer to the patient. Traditional regulatory models built around large-scale, standardized pharmaceutical production are increasingly being challenged by decentralized manufacturing, AI-enabled biological design, and mechanism-driven clinical validation strategies.

In 2025 and early 2026, global regulatory agencies signalled important shifts toward risk-based, science-led oversight frameworks. These changes reflect a broader regulatory evolution—balancing faster patient access to innovative therapies with sustained focus on safety, quality, and lifecycle evidence generation.

The following sections explore how global regulators are evolving their expectations across manufacturing quality, clinical evidence generation, decentralized production models, and lifecycle risk management to support innovation while maintaining rigorous patient safety standards.

Cell & Gene Therapy/ATMP: Advanced Therapy Global Oversight

Advanced therapies continued to drive regulatory evolution in 2025. Agencies recognised that personalised medicines, decentralised manufacturing, and autologous therapies cannot fit traditional regulatory paradigms and have suggested the following reforms-:

· Flexible CMC Expectations

Update: In January 2026, the FDA signalled a more flexible approach to Chemistry, Manufacturing, and Controls (CMC) for cell and gene therapies. (1)

Implications: This flexibility accelerates clinical development and commercialization of personalized therapies, but requires robust risk justification, strong process monitoring, and clear documentation to maintain compliance and inspection readiness. Regulatory flexibility does not reduce scientific rigor. With smaller clinical datasets, regulators rely more on manufacturing consistency, requiring strong process understanding, validated assays, qualified materials, and robust comparability and process control strategies.

· EU Pharmaceutical Legislation Overhaul – Committee Integration Reform

Update: In December 2025, the EU agreed on a major reform of its pharmaceutical legislation, proposing to streamline EMA’s governance structure by integrating the Committee for Advanced Therapies (CAT) into the Committee for Medicinal Products for Human Use (CHMP), pending final endorsement by the European Parliament and Council (2).

Implications: For ATMP sponsors, this reform may improve procedural consistency and reduce fragmentation across therapeutic areas. However, it also raises uncertainty regarding the accessibility and depth of ATMP-specific expertise previously concentrated within the CAT. Companies should anticipate potential shifts in scientific engagement dynamics and ensure clear, well-substantiated regulatory strategies when interacting within the evolving EU framework. More structured justification of ATMP-specific aspects and early, well-prepared regulatory engagement will be important to manage potential shifts in expertise and reduce uncertainty.

· FDA’s “Plausible Mechanism” Approval Pathway for Personalized Therapies

Update: In November 2025, the FDA signalled openness to mechanism-anchored approvals for certain personalized therapies where large, statistically powered trials are not feasible. (3)

Implications: For companies, this means smaller clinical datasets may be acceptable — but only if supported by a strong biological rationale, aligned biomarker strategy, robust CMC controls, and a clear post-approval evidence plan. This shifts regulatory emphasis from data volume to scientific coherence and manufacturing reliability. Regulators will rely more on reproducibility, mechanism-relevant potency assays, product characterization, and well-justified CQAs to support the benefit-risk assessment.

· EMA ATMP Regulatory Focus & Concept Papers

Update: In July 2025, EMA released concept papers and updated Q&As regarding ATMP manufacturing and quality expectations. Revisions are being planned for EudraLex Volume 4, Part IV. (4)

Implications: For ATMP developers, this signals stronger alignment between innovation-driven development models and established GMP quality standards in the EU. Companies should anticipate more explicit scrutiny of process validation, comparability following manufacturing changes, potency assays, and lifecycle quality management.

· European Pharmacopoeia (Ph. Eur.) Updates

Update: In July 2025, Ph. Eur. introduced general texts for mRNA vaccine substances and other ATMP components. (5)

Implications: For developers of mRNA vaccines and other ATMPs, the new Ph. Eur. general texts introduce clearer, harmonised quality benchmarks that will directly influence specification setting, analytical method validation, and stability strategy. Companies should reassess their control strategies to ensure alignment with updated identity, purity, and potency expectations, particularly for personalised or platform-based mRNA products.

· ATMP Clinical Trial Guidance (EMA/CHMP)

Update: In July 2025, EMA issued updated guidance on data requirements for ATMP clinical trial applications, covering non-clinical, quality, and clinical sections. (6)

Implications: For ATMP sponsors, the updated guidance clarifies data expectations across non-clinical, quality, and clinical sections, enabling more structured and predictable clinical trial applications. Companies should align early development plans with these harmonised requirements, particularly around staged non-clinical testing, CMC documentation for investigational products, and risk-based clinical design.

· Decentralized / Point-of-Care Manufacturing

Update: In June 2025, MHRA launched the decentralised / point-of-care (PoC) manufacturing framework that enables near-patient manufacturing of personalized therapies. (7)

Implications: While this approach can reduce turnaround times and improve patient access, it shifts regulatory focus to network-wide quality governance. Companies must ensure standardized processes, digital batch traceability, validated equipment, and consistent GMP compliance across decentralized sites. Inspection readiness will depend less on a single facility and more on the strength of centralized QMS oversight, data integrity, secure chain-of-identity and custody controls, supported by clear QP release frameworks and remote audit capabilities across the entire manufacturing network.

· MHRA’s Personalized Cancer Vaccines Guidance

Update: In February 2025, the UK MHRA issued draft guidance on individualized mRNA cancer vaccines (8), outlining regulatory expectations for both product development and the use of AI/ML-based bioinformatics algorithm for neoantigen identification/selection.

Implications: The MHRA draft guidance adopts a flexible, risk-based approach for individualized mRNA cancer vaccines, aligned with FDA’s recent CMC flexibility. AI/ML bioinformatics tools are increasingly expected to meet validation, traceability, and lifecycle software assurance requirements, particularly when classified as Software as a Medical Device (SaMD) or GMP-relevant digital systems, requiring early software validation and integrated regulatory, clinical, and data oversight to ensure inspection readiness.

· Platform Technologies

Update: Regulators are increasingly engaging with platform-based development models for advanced therapies. In the U.S., the FDA’s Platform Technology Designation Program (9) allows sponsors to leverage prior data across products built on a common technology. In the EU, the proposed pharmaceutical reform and ongoing EMA scientific dialogue signal openness to modular and prior-knowledge approaches, with conceptual parallels to established frameworks such as the Vaccine Antigen Master File (VAMF) (10) and Plasma Master File (PMF) (11). However, a formal EU platform authorization pathway has not yet been fully defined.

Implications: For developers using viral vectors, gene editing systems, or mRNA delivery platforms, regulatory recognition of platform technologies could reduce duplication and accelerate development. At the same time, authorities are likely to require strong characterization, comparability strategies, and quality controls. Early regulatory engagement and a well-structured scientific justification will be critical to realizing potential efficiencies.

· Global Harmonization Efforts

Update: FDA’s CBER continues to emphasize CGT-specific guidance; EMA aligns quality and manufacturing expectations. Cross-region discussions focus on harmonizing early-phase clinical and manufacturing requirements. (12, 13, 14). The FDA, EMA, and MHRA have also established structured expedited pathways to support advanced therapies (15, 16).

Expedited review pathways for advanced therapies:

Implications: Supports multinational trials and reduces duplication of compliance efforts. While harmonization efforts reduce redundancy in regulatory submissions, sponsors must still navigate differences in regional inspection expectations, data presentation depth, and post-approval monitoring requirements. Additionally, expedited approval pathways enable earlier patient access to innovative therapies and can significantly shorten development timelines. However, they shift regulatory expectations toward stronger early scientific justification, robust CMC control strategies, and well-defined post-approval evidence plans.

• Risk-Based Lifecycle Approaches

Update: Regulators increasingly accept risk-based quality frameworks for CGT products.

Implications: Allows flexibility in early-stage product development while maintaining patient safety and long-term monitoring. For CGT developers, this requires deeper process understanding, clearly defined critical quality attributes, and proactive comparability planning as products evolve.

Conclusion:

The regulatory landscape for cell and gene therapies is entering a new phase characterized by science-led flexibility, digital manufacturing integration, and lifecycle quality governance. As regulatory agencies continue to adapt to the realities of personalized medicine, developers must align innovation strategies with robust evidence generation and quality control frameworks.

Future success in advanced therapy development will depend not only on scientific and clinical breakthroughs but also on investments in digital quality infrastructure, data integrity governance, and early regulatory engagement strategies. Organizations that adopt integrated regulatory, clinical, and manufacturing strategies will be best positioned to lead the next wave of advanced therapy innovation.

References:

1. Flexible Requirements for Cell and Gene Therapies to Advance Innovation | FDA
2. EMA welcomes political agreement on new EU pharmaceutical legislation | European Medicines Agency (EMA)
3. Prasad, V., & Makary, M. A. (2025). FDA’s new plausible mechanism pathway. The New England Journal of Medicine, 393(23), 2365–2367. https://doi.org/10.1056/NEJMsb2512695
4. Concept paper on the revision of annex 1 of the guidelines on good manufacturing practice – manufacture of sterile medicinal products
5. European Pharmacopoeia Commission adopts first three general texts on mRNA vaccines – European Directorate for the Quality of Medicines & HealthCare
6. Guideline on quality, non-clinical and clinical requirements for investigational advanced therapy medicinal products in clinical trials
7. Human medicines Modular Manufacture and Point of Care 2025 – GOV.UK
8. Individualised_mRNA_cancer_immunotherapies_0.6.5.pdf
9. Platform Technology Designation Program for Drug Development | FDA
10. Requirements for vaccine antigen master file certification – Scientific guideline | European Medicines Agency (EMA)
11. Plasma master file (PMF) certification | European Medicines Agency (EMA)
12. Cellular & Gene Therapy Products | FDA
13. Advanced therapy medicinal products: Overview | European Medicines Agency (EMA)
14. EMA Guideline On Clinical-Stage ATMPs Comes Into Effect On The Verge Of Convergence
15. https://www.biophorum.com/download/supporting-the-need-for-global-regulatory-harmonization/
16. The MHRA-NICE Accelerated Aligned Pathway Pilot. – Pharma Design